Hikma and Vectura plan to develop generic versions of GSK's Ellipta portfolio, utilizing Vectura's proprietary "open-inhale-close" dry powder inhaler device.
Lannett is launching generic versions of Biaxin and Comtan, which market values of about $8 million and $24 million respectively, through an expanded agreement with Sunshine Lake.